Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Macropa-NCS, conjugated to Anti-Human HER2 and the prostate-specific membrane antigen-targeting compound RPS-070, serves as a promising therapeutic radionuclide for soft-tissue metastases treatment. Its precursor, Macropa-NH2 hydrochloride, facilitates its synthesis.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 18,200 | 5日内发货 | ||
50 mg | ¥ 23,700 | 5日内发货 | ||
100 mg | ¥ 37,400 | 5日内发货 | ||
200 mg | 待询 | 5日内发货 | ||
500 mg | 待询 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 7,135 | 5日内发货 |
产品描述 | Macropa-NCS, conjugated to Anti-Human HER2 and the prostate-specific membrane antigen-targeting compound RPS-070, serves as a promising therapeutic radionuclide for soft-tissue metastases treatment. Its precursor, Macropa-NH2 hydrochloride, facilitates its synthesis. |
体外活性 | A white suspension of 11?4TFA (0.1598 g, 0.16 mmol) and Na2CO3 (0.2540 g, 2.4 mmol) was heated at reflux in acetone (10 mL) for 30 min before the slow addition of CSCl2 (305 μL of CSCl2, 85%, Acros Organics).?The resulting orange suspension was heated at reflux for 3 h and then concentrated at 30 °C under reduced pressure to a pale-orange solid.?The solid was dissolved portionwise in 10% ACN/H2O containing 0.2% TFA (8 mL total), filtered, and immediately purified by preparative HPLC using Method C. Pure fractions were combined, concentrated at RT under reduced pressure to remove the organic solvent, and then lyophilized.?Fractions that were not able to be concentrated immediately were frozen at -80 °C.?Isothiocyanate 12 was obtained as a mixture of white and pale-yellow solid (0.0547 g) and was stored at –80 °C in a jar of Drierite.?A stock solution containing 4.4 mg/mL of macropa-NCS was prepared in 0.1 M pH 9.1 NaHCO3 buffer containing 0.154 M NaCl and was stored at -80 °C.?To a portion of Tmab in saline (74 μL) were added macropa-NCS (52 μL) and NaHCO3 buffer (266 μL), so that the final concentrations of Tmab and macropa-NCS were 5.1 mg/mL and 0.59 mg/mL, respectively.?Macropa-NCS was estimated to be in 16-fold molar excess to Tmab based on a molecular weight of 1045.76 g/mol for macropa-NCS (tetra-TFA salt)[1]. |
分子量 | 584.06 |
分子式 | C26H38ClN5O8 |
CAS No. | 2443966-86-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (142.67 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7122 mL | 8.5608 mL | 17.1215 mL | 42.8038 mL |
5 mM | 0.3424 mL | 1.7122 mL | 3.4243 mL | 8.5608 mL | |
10 mM | 0.1712 mL | 0.8561 mL | 1.7122 mL | 4.2804 mL | |
20 mM | 0.0856 mL | 0.428 mL | 0.8561 mL | 2.1402 mL | |
50 mM | 0.0342 mL | 0.1712 mL | 0.3424 mL | 0.8561 mL | |
100 mM | 0.0171 mL | 0.0856 mL | 0.1712 mL | 0.428 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Macropa-NH2 hydrochloride 2443966-86-5 Others MacropaNH2 hydrochloride Macropa-NH-2 hydrochloride Macropa NH2 hydrochloride Macropa-NH2 Hydrochloride Inhibitor inhibitor inhibit